The Expression Of DNMT1and HMGA2and The Significance Of Them In The Bladder Urothelial Carcinoma

Background:Bladder cancer,(Bladder cancerBC) in the current top male urogenital system tumors, according to a recent epidemiological studies have shown that the incidence of BC in the sixth global malignant disease", BC found new cases per year in the United States more than5000cases, in the domestic, the male incidence of bladder cancer ranked eighth, women ranked tenth, of which more than90%of bladder Urothelial carcinoma (bladder Urothelial carcinoma, BUC) is the main pathological type, BC incidence but the methods of diagnosis and treatment of the BUC did not have a historic breakthrough, so make a diagnosis and give treatment of isObjective:By detecting the DNA methyltransferase (DNMT1) and high mobility group protein A2(HMGA2) in bladder urothelial carcinoma in the expression changes, explore HMGA2and DNMT1in bladder urothelial carcinoma clinical pathological staging and prognosis and diagnosis value of significance.Methods:From2012January to2014February were collected in Henan Province People’s Hospital Department of Urology operation specimens. Medical Collage. The48cases of carcinoma tissue were from the patients who have been postoperative pathology diagnosed with bladder urothelial carcinoma and the patients didn’t have chemotherapy and radiation before surgery, and take another20cases of normal bladder tissue from healthy person as control (the bladder microscopical examination were obtained by the agreement of the patients). Each person’s tissue specimen are divided into two parts, one part have be taken into liquid nitrogen storage in order to store for the experiment of Western Blotting/SP to detect and observe the protein expression level of DNMT1and HMGA2, RT-PCR to detect and observeDNMT1and HMGA2mRNA expression of the bladder urothelial carcinoma tissue and normal bladder mucous membrane tissues.Results:(1) Western Blotting results show that DNMT1and HMGA2protein in bladder urothelial carcinoma tissues were compared to the normal bladder tissue, and the expression quantity increased obviously, have the remarkable statistical differences (P<0.05).(2) Immunohistochemistry (SP) results showed that DNMT1and HMGA2protein in bladder urothelial carcinoma tissue positive expression rate of68.5%and62.9%, respectively, to25.0%of the expression is significantly higher than normal bladder tissue (chi-square=6.872, P=6.872) and20.0%, the difference was statistically significant (chi-square=8.637, P=8.637)(3) DNMT1and HMGA2in pathology classification level is high, the invasive and associated with metastasis of bladder urothelial carcinoma specimens in the positive expression rate is significantly higher than pathology classification level is low, the superficial, non tumor metastasis of bladder urothelial carcinoma specimens positive expression rate, the difference was statistically significant (P<0.05)(4) RT-PCR results show that DNMT1and HMGA2genes in bladder urothelial carcinoma tissues were compared to the normal bladder tissue, and the expression quantity increased obviously, have the remarkable statistical differences (P<0.05).(5) The expression level of changes in patients with age, sex, tumor size, no positive correlation (P>0.05). (6) The positive expression rate for DNMT1in bladder urothelial carcinoma tissue is significant correlated (r=0.672, P=0.04) with HMGA2in bladder urothelial carcinoma tissue.Conclusion:(1)DNMT1and HMGA2protein had high expression in the bladder urothelial carcinoma tissue, and closely related with pathologic stage, invasive and metastatic.(2).DNMT1and HMGA2genes had over expression in bladder urothelial carcinoma tissues(3). DNMT1and HMGA2potential index can be used as judgment occurrence and development of bladder cancer.(4).DNMT1and HMGA2protein were positively related in the bladder urothelial carcinoma tissues.